Biotricity, Inc. - Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)		3 Months Ended
		Jun. 30, 2017	Jun. 30, 2016
Income Statement
Revenue
Expenses:
General and administrative expenses	[1]	1,066,659	534,468
Research and development expenses		315,110	266,370
Total Operating Expenses		1,381,769	800,808
Accretion expense	[2]	879,416	120,531
Change in fair value of derivative liabilities	[3]	42,128	123,268
Net loss before income taxes		(2,303,313)	(1,044,607)
Income taxes
Net loss		(2,303,313)	(1,044,607)
Translation adjustment		(86,490)	(129,591)
Comprehensive loss		$ (2,389,803)	$ (1,174,198)
Loss per share, basic and diluted		$ (0.084)	$ (0.042)
Weighted average number of common and exercisable shares outstanding		27,512,483	24,999,978

[1] See Notes 7, 8, and 9

[2] See Note 5

[3] See Note 6